Acacia Pharma has a late-stage pipeline of nausea and vomiting product candidates for surgical and cancer patients; large and growing markets with significant unmet medical need.
Post-operative nausea & vomiting (PONV)
PONV is a common complication of surgery, occurring in approximately 30% of surgical patients and up to 80% of high-risk patients.
View PONV video
Chemotherapy induced nausea & vomiting (CINV)
CINV is one of the most common and feared side effects of cancer chemotherapy.
Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020
Interim Results for the Six Months ended 30 June 2019
Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession
View all news